Literature DB >> 9090449

Coincidence between spontaneous release of interferon and tumor necrosis factor by colostral leukocytes and the production of a colostrinine by human mammary gland after normal delivery.

E Piasecki1, A D Inglot, M Winiarska, K Krukowska, M Janusz, J Lisowski.   

Abstract

We have tentatively identified colostrinines as novel cytokines produced by the mammary gland after delivery and detectable in colostrum. The primary colostrinine, the proline-rich polypeptide, was isolated from ovine colostrum in 1974. It is generally understood that the various factors present in colostrum play a pivotal role in transmitting of passive or active immunity from mother to child. We have found previously that both ovine and human colostrinines are inducers of interferon (IFN) gamma and other cytokines. In this paper, we reported that the leukocytes isolated from human colostrum donated by healthy mothers at 1-9 days after delivery, produced IFNs and tumor necrosis factors (TFNs) spontaneously. The release of IFNs and TNFs coincided with production of a colostrinine that has been isolated from the human colostrum samples and partially characterized. Our results suggest that the maximum production of colostrinine occurs 3 days after delivery. The tolerance (hyporeactivity) of the colostral leukocytes to IFN inducers and the modulation of the TNF response may be the late effects of the colostrinine release.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9090449

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  2 in total

1.  Towards an understanding of biological role of colostrinin peptides.

Authors:  M L Kruzel; M Janusz; J Lisowski; R V Fischleigh; J A Georgiades
Journal:  J Mol Neurosci       Date:  2001-12       Impact factor: 3.444

2.  Immunomodulatory activity accompanying chicken egg yolk immunoglobulin Y.

Authors:  A Polanowski; A Zabłocka; A Sosnowska; M Janusz; T Trziszka
Journal:  Poult Sci       Date:  2012-12       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.